R&D That's More Than Skin Deep

R&D That's More Than Skin Deep

06.13.11 | By Kate Connors

Summer is finally upon us, and though at times it almost seems too steamy to venture outside, it serves as a good reminder about the importance of taking care of your skin.

We've come far in terms of our skin's health. My mother tells me about her childhood, spending summer days at the beach with her Irish skin exposed to the sun's harmful rays. She made sure that I grew up with sunscreen at arm's reach all summer long.
Unfortunately, despite our improved prevention, for many people, the damage is already done. But a new report from PhRMA, finding 277 medicines currently in development to treat skin diseases, shows that patients now confronting the effects of years-old sun damage have reason to hope.
The report found that America's biopharmaceutical research companies are developing 74 medicines for skin cancers, including 63 for melanoma - the most common form of cancer in the U.S., affecting more than 68,000 Americans each year.
It's worth noting, of course, that though summer reminds us about the threat of skin cancer, there are many skin diseases that are not cancers, but are equally painful and costly.
For example, skin and soft tissue infections account for nearly 14 million outpatient visits each year; 60 medicines are in development now to treat those. And psoriasis, which affects 7.5 million people in the U.S., currently is a challenge to treat. But 41 medicines are being studied to treat it right now.
To see the report in full, and to get some information about skin cancer in your state from our interactive map, click here.

More On PhRMA — powered by PhRMApedia


Cost in Context